Ursodeoxycholic acid treatment in patients with cystic fibrosis at risk for liver disease

Digestive and Liver Disease

Volumn 42, Issue 6, 2010, Pages 428-431

  Siano, Maria ^a   De Gregorio, Fabiola ^a   Boggia, Bartolo ^a   Sepe, Angela ^a   Ferri, Pasqualina ^a   Buonpensiero, Paolo ^a   Di Pasqua, Antonio ^a   Raia, Valeria ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Cystic fibrosis; Liver disease; Meconium ileus; Ursodeoxycholic acid

Indexed keywords

URSODEOXYCHOLIC ACID; CHOLAGOGUE;

ARTICLE; CHILD; CHRONIC LIVER DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTIC FIBROSIS; DIABETES MELLITUS; DRUG RESPONSE; EARLY INTERVENTION; FEMALE; HIGH RISK PATIENT; HUMAN; MALE; MECONIUM ILEUS; OUTCOME ASSESSMENT; PREVALENCE; PRIORITY JOURNAL; PSEUDOMONAS INFECTION; CHRONIC DISEASE; COMPARATIVE STUDY; COMPLICATION; DOSE RESPONSE; FOLLOW UP; INFANT; ITALY; LIVER DISEASES; MORBIDITY; PRESCHOOL CHILD; RETROSPECTIVE STUDY; SURVIVAL RATE; TREATMENT OUTCOME; TRENDS;

CHILD; CHILD, PRESCHOOL; CHOLAGOGUES AND CHOLERETICS; CHRONIC DISEASE; CYSTIC FIBROSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFANT; ITALY; LIVER DISEASES; MALE; MORBIDITY; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME; URSODEOXYCHOLIC ACID;

EID: 77952742282     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dld.2009.07.022     Document Type: Article

References (28)

1. Ratjen F., Doring G. Cystic fibrosis. Lancet 2003, 361:681-689.
2. Karem B., Rommens J.M., Buchanan J.A., et al. Identification of the cystic fibrosis gene: genetic analysis. Science 1989, 245:1073-1080.
3. Gregory R.J., Cheng S.H., Rich D.P., et al. Expression and characterization of the cystic fibrosis transmembrane conductance regulator. Nature 1990, 347:382-386.
4. Rozmahel R., Wilschanski M., Matin A., et al. Modulation of disease severity in cystic fibrosis transmembrane conductance regulator deficient mice by a secondary genetic factor. Nat Genet 1996, 12:280-287.
5. Scott-Jupp R., Lama L., Tanner M.S. Prevalence of liver disease in cystic fibrosis. Arch Dis Child 1991, 6:698-701.
6. Colombo C., Battezzati P.M. Liver involvement in cystic fibrosis: primary organ damage or innocent bystander?. J Hepatol 2004, 41:1041-1044.
7. Cohn J.A., Strong T.V., Picciotto M.R., et al. Localization of the cystic fibrosis transmembrane conductance regulator in human bile duct epithelial cells. Gastroenterology 1993, 105:1857-1864.
8. Diwakar V., Pearson L., Beath S. Liver disease in children with cystic fibrosis. Peadiatr Respir Rev 2001, 2:340-349.
9. Colombo C., Battezzati P.M., Crosignani A., et al. Liver disease in cystic fibrosis: a prospective study on incidence, risk factors, and outcome. Hepatology 2002, 36:1374-1382.
10. Colombo C., Apostolo M.G., Ferrari M., et al. Analysis of risk factors for the development of liver disease associated with cystic fibrosis. J Pediatr 1994, 24:393-399.
11. Colombo C., Costantini D., Rocchi A., et al. Effects of liver transplantation on nutritional status of patients with cystic fibrosis. Transplant International 2005, 18:246-255.
12. Douglas M.H., Gurie M.V. Hepatoprotective properties of ursodeoxycholic acid. Gastroenterology 1993, 104:1865-1870.
13. Guldutuna S., Zimmer G., Imhof M., et al. Molecular aspects of membrane stabilization by ursodeoxycholate. Gastroenterology 1993, 104:1736-1744.
14. Cotting J., Lentze M., Reichen J. Effects of ursodeoxicholic acid treatment on nutrition and liver function in patients with cystic fibrosis and longstanding cholestasis. Gut 1990, 31:918-921.
15. Poupon R.E., Lindor K.D., Cauch-Dudek K., et al. Combined analysis of randomized controlled trials of ursodeoxicolic acid in primary biliary cirrhosis. Gastroenterology 1997, 113:884-890.
16. Colombo C., Setchell K.D., Podda M., et al. Effects of ursodeoxycolic acid therapy for liver disease associated with cystic fibrosis. J Pediatr 1990, 117:482-489.
17. Galabert C., Monet J.C., Lengrand D., et al. Effects of ursodeoxycolic acid on liver function in patients with cystic fibrosis and chronic cholestasis. J Pediatr 1992, 121:138-141.
18. Colombo C., Castellani M.R., Balistreri W.F., et al. Scintigraphic documentation of an improvement in epatobiliary excretory function after treatment with ursodeoxicolic acid in patients with cystic fibrosis and associated liver disease. Hepatology 1992, 15:677-684.
19. Nousia Arvanitakis S., Fotoulaki M., Economou H., et al. Long term prospective study of effect of ursodeoxicolic acid on cystic fibrosis-related liver disease. J Clin Gastroenterol 2001, 32:324-328.
20. Colombo C., Battezzati P.M., Podda M., et al. Ursodeoxycholic acid for liver disease associated with cystic fibrosis: a double-blind multicenter trial. Hepatology 1996.
21. Sinaasappel M., Stern M., Littlewood J., et al. Nutrition in patients with cystic fibrosis: a European Consensus. J Cystic Fibrosis 2002, 1:51-75. 1484-90.
22. Munck A., Gerardin M., Alberti C., et al. Clinical outcome of cystic fibrosis presenting with or without meconium ileus: a matched cohort study. J Pediatr Surg 2006, 41:1556-1560.
23. Evans A.K.C., Fitzgerald, McKay K.O. The impact of meconium ileus on the clinical course of children with cystic fibrosis. Eur Respir J 2001, 18:784-789.
24. Li Z., Lai H.J., Kosorok M.R., et al. Longitudinal pulmonary status of cystic fibrosis children with meconium ileus. Pediatr Pulmonol 2004, 38:277-284.
25. Lai H.C., Kosorok M.R., Laxova A., et al. Nutritional status of patients with cystic fibrosis with meconium ileus: a comparison with patients without meconium ileus and diagnosed early through neonatal screening. Pediatrics 2000, 105:53-61.
26. Efrati O., Nir J., Fraser D., et al. Meconium Ileus in CF patients is not a risk factor for clinical deterioration and survival: the Israeli multi-center study. Eur J Gastroenterol Hepatol 2003, 15:1073-1078.
27. Minicucci L., Lorini R., Giannattasio A., et al. Liver disease as risk factor for cystic fibrosis-related diabetes development. Acta Paediatr 2007, 96:736-739.
28. Fiorotto R., Spirlì C., Fabris L., et al. Ursodeoxycholic acid stimulates cholangiocyte fluid secretion in mice via CFTR-dependent ATP secretion. Gastroenterology 2007, 133:1603-1613.